Shares of pharmaceutical companies declined after U.S. President Donald Trump announced plans to lower U.S. prescription drug ...

Shares of pharmaceutical companies fell across the world after US President Donald Trump said he planned to order a cut in US ...

Kroger, Albertsons and others allege an unlawful monopoly in one legal case and aim to recover overcharges for a drug in ...

Takeda will be investing approximately $30 billion into its U.S. operations over the next five years, the company announced.

Takeda was scrambling to accommodate for rapidly sinking profits from the hasty decline of ADHD mainstay Vyvanse with a 140 ...

Takeda forecast annual operating profit to rise 39% to Y475.00 billion. It expects savings from its enterprise-wide efficiency program, significant declines in restructuring expenses and lower ...

Recursion Pharmaceuticals, Inc.’s RXRX share price has dipped by 6.86%, which has investors questioning if this is right time to buy.

One company to watch right now is Takeda Pharmaceutical Co. (TAK). TAK is currently sporting a Zacks Rank of #2 (Buy), as well as a Value grade of A. Another valuation metric that we should ...

We have seen 140 institutional investors add shares of TAK stock to their portfolio, and 133 decrease their positions in their most recent quarter. Here are some of the largest recent moves: Wall ...

Sequeira, President of the Global Portfolio Division at Takeda Pharmaceutical Company, to Organon’s Board of Directors, effective July 1, 2025. Ms. Sequeira will serve on the Board’s Talent ...

Read Our Latest Stock Analysis on TAK Takeda Pharmaceutical Stock Down 3.0 % TAK stock opened at $14.74 on Monday. The company has a current ratio of 1.31, a quick ratio of 0.72 and a debt-to ...

The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.72 and a current ratio of 1.31. Get Takeda Pharmaceutical alerts: Takeda Pharmaceutical (NYSE:TAK – Get Free Report ...